Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review - Report - MDSpire
Advertisement
Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review
Clinical Report: Uncommon Spontaneous Intracerebral Hemorrhage Linked to Lenvatinib
Overview
This report details a rare case of spontaneous lobar intracerebral hemorrhage (ICH) in a patient with advanced hepatocellular carcinoma (HCC) undergoing lenvatinib therapy. The findings underscore the potential risk of ICH associated with lenvatinib, even in the absence of traditional risk factors.
Background
Expand on the mechanism of lenvatinib's anti-angiogenic properties and their link to ICH.
Data Highlights
No numerical data or trial data were presented in the article.
Key Findings
A 54-year-old male with advanced HCC developed spontaneous lobar ICH after seven months of lenvatinib therapy.
The patient had no traditional risk factors for ICH, such as hypertension or structural brain lesions.
Initial imaging showed a large lobar ICH without evidence of metastatic tumor or vascular abnormalities.
Thrombocytopenia was noted but was insufficient to fully explain the hemorrhage.
The ICH initially improved but later exacerbated, leading to the discontinuation of lenvatinib.
This case highlights the need for vigilance in monitoring neurological symptoms in patients on lenvatinib.
Clinical Implications
Healthcare professionals should be aware of the potential risk of ICH in patients receiving lenvatinib, even in the absence of traditional risk factors. Regular monitoring for new neurological symptoms is essential to ensure timely intervention and management.
Conclusion
This case emphasizes the importance of recognizing the potential for spontaneous ICH in patients treated with lenvatinib for advanced HCC. Ongoing vigilance is necessary to mitigate risks associated with this therapy.
